Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation
Marc S. Sabatine, M.D., M.P.H., Christopher P. Cannon, M.D., C. Michael Gibson, M.D., Jose L. López-Sendón, M.D., Gilles Montalescot, M.D., Pierre Theroux, M.D., Marc J. Claeys, M.D., Ph.D., Frank Cools, M.D., Karen A. Hill, B.A., Allan M. Skene, Ph.D., Carolyn H. McCabe, B.S., Eugene Braunwald, M.D., for the CLARITYTIMI 28 Investigators
Background A substantial proportion of patients receiving fibrinolytictherapy for myocardial infarction with ST-segment elevationhave inadequate reperfusion or reocclusion of the infarct-relatedartery, leading to an increased risk of complications and death.
Methods We enrolled 3491 patients, 18 to 75 years of age, whopresented within 12 hours after the onset of an ST-elevationmyocardial infarction and randomly assigned them to receiveclopidogrel (300-mg loading dose, followed by 75 mg once daily)or placebo. Patients received a fibrinolytic agent, aspirin,and when appropriate, heparin (dispensed according to body weight)and were scheduled to undergo angiography 48 to 192 hours afterthe start of study medication. The primary efficacy end pointwas a composite of an occluded infarct-related artery (definedby a Thrombolysis in Myocardial Infarction flow grade of 0 or1) on angiography or death or recurrent myocardial infarctionbefore angiography.
Results The rates of the primary efficacy end point were 21.7percent in the placebo group and 15.0 percent in the clopidogrelgroup, representing an absolute reduction of 6.7 percentagepoints in the rate and a 36 percent reduction in the odds ofthe end point with clopidogrel therapy (95 percent confidenceinterval, 24 to 47 percent; P<0.001). By 30 days, clopidogreltherapy reduced the odds of the composite end point of deathfrom cardiovascular causes, recurrent myocardial infarction,or recurrent ischemia leading to the need for urgent revascularizationby 20 percent (from 14.1 to 11.6 percent, P=0.03). The ratesof major bleeding and intracranial hemorrhage were similar inthe two groups.
Conclusions In patients 75 years of age or younger who havemyocardial infarction with ST-segment elevation and who receiveaspirin and a standard fibrinolytic regimen, the addition ofclopidogrel improves the patency rate of the infarct-relatedartery and reduces ischemic complications.
Source Information
From the TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (M.S.S., C.P.C., C.M.G., C.H.M., E.B.); Hospital Universitario Gregorio Marañon, Madrid (J.L.L.-S.); Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris (G.M.); the Montreal Heart Institute, Montreal (P.T.); the Department of Cardiology, University Hospital Antwerp, Edegem, Belgium (M.J.C.); Academisch Ziekenhuis Klina, Brasschaat, Belgium (F.C.); and Nottingham Clinical Research Group, Nottingham, United Kingdom (K.A.H., A.M.S.). This article was published at www.nejm.org on March 9, 2005.
Address reprint requests to Dr. Sabatine at the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at msabatine{at}partners.org.
Moukarbel, G. V., Signorovitch, J. E., Pfeffer, M. A., McMurray, J. J. V., White, H. D., Maggioni, A. P., Velazquez, E. J., Califf, R. M., Scheiman, J. M., Solomon, S. D.
(2009). Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J
0: ehp256v1-ehp256
[Abstract][Full Text]
Cantor, W. J., Fitchett, D., Borgundvaag, B., Ducas, J., Heffernan, M., Cohen, E. A., Morrison, L. J., Langer, A., Dzavik, V., Mehta, S. R., Lazzam, C., Schwartz, B., Casanova, A., Goodman, S. G., the TRANSFER-AMI Trial Investigators,
(2009). Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. NEJM
360: 2705-2718
[Abstract][Full Text]
APPRAISE Steering Committee and Investigators,
(2009). Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation
119: 2877-2885
[Abstract][Full Text]
Van de Werf, F.
(2009). Year 2008 ESC ST-segment elevation myocardial infarction guidelines: implications for the interventional cardiologist--from evidence to recommendations and practice. Eur Heart J Suppl
11: C31-C37
[Full Text]
Cleanthis, M, Flather, M.
(2009). The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective. Clin Risk
15: 106-108
[Full Text]
Tousoulis, D., Briasoulis, A., Dhamrait, S. S, Antoniades, C., Stefanadis, C.
(2009). Effective platelet inhibition by aspirin and clopidogrel: where are we now?. Heart
95: 850-858
[Full Text]
Blasco-Colmenares, E., Perl, T. M., Guallar, E., Baumgartner, W. A., Conte, J. V., Alejo, D., Pastor-Barriuso, R., Sharrett, A. R., Faraday, N.
(2009). Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery. Arch Intern Med
169: 788-795
[Abstract][Full Text]
Desai, N. R., Mega, J. L., Jiang, S., Cannon, C. P., Sabatine, M. S.
(2009). Interaction between cigarette smoking and clinical benefit of clopidogrel.. J Am Coll Cardiol
53: 1273-1278
[Abstract][Full Text]
Chua, D., Ignaszewski, A.
(2009). Clopidogrel in acute coronary syndromes. BMJ
338: b1180-b1180
[Full Text]
Jeong, Y. H., Lee, S.-W., Choi, B.-R., Kim, I.-S., Seo, M.-K., Kwak, C. H., Hwang, J.-Y., Park, S.-W.
(2009). Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.. J Am Coll Cardiol
53: 1101-1109
[Abstract][Full Text]
Bogaty, P.
(2009). Duration of Symptoms Is Not Always the Key Modulator of the Choice of Reperfusion for ST-Elevation Myocardial Infarction. Circulation
119: 1304-1310
[Full Text]
Matheny, M. E., Morrow, D. A., Ohno-Machado, L., Cannon, C. P., Sabatine, M. S., Resnic, F. S.
(2009). Validation of an Automated Safety Surveillance System with Prospective, Randomized Trial Data. Med Decis Making
29: 247-256
[Abstract]
Cohen, M.
(2009). Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care. Mayo Clin Proc.
84: 149-160
[Abstract][Full Text]
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N., Steg, P. G., Ferrieres, J., Danchin, N., Becquemont, L., the French Registry of Acute ST-Elevation and Non-,
(2009). Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. NEJM
360: 363-375
[Abstract][Full Text]
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., Sabatine, M. S.
(2009). Cytochrome P-450 Polymorphisms and Response to Clopidogrel. NEJM
360: 354-362
[Abstract][Full Text]
Terpening, C.
(2009). An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events. J Am Board Fam Med
22: 51-56
[Abstract][Full Text]
Authors/Task Force Members, , Van de Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C., Crea, F., Falk, V., Filippatos, G., Fox, K., Huber, K., Kastrati, A., Rosengren, A., Steg, P. G., Tubaro, M., Verheugt, F., Weidinger, F., Weis, M., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Silber, S., Aguirre, F. V., Al-Attar, N., Alegria, E., Andreotti, F., Benzer, W., Breithardt, O., Danchin, N., Mario, C. D., Dudek, D., Gulba, D., Halvorsen, S., Kaufmann, P., Kornowski, R., Lip, G. Y. H., Rutten, F.
(2008). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. Eur Heart J
29: 2909-2945
[Full Text]
Dudek, D., Rakowski, T., Dziewierz, A., Kleczynski, P.
(2008). PCI after lytic therapy: when and how?. Eur Heart J Suppl
10: J15-J20
[Abstract][Full Text]
Garg, P., Normand, S.-L. T., Silbaugh, T. S., Wolf, R. E., Zelevinsky, K., Lovett, A., Varma, M. R., Zhou, Z., Mauri, L.
(2008). Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus: Results From the Massachusetts Data Analysis Center Registry. Circulation
118: 2277-2285
[Abstract][Full Text]
Berger, J. S., Frye, C. B., Harshaw, Q., Edwards, F. H., Steinhubl, S. R., Becker, R. C.
(2008). Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery: A Multicenter Analysis. J Am Coll Cardiol
52: 1693-1701
[Abstract][Full Text]
Goldman, L., Gaspoz, J.-M.
(2008). Cost-Effectiveness of Clopidogrel: Seeing through the Smoke. Med Decis Making
28: 803-809
[Abstract]
Zimarino, M., De Caterina, R.
(2008). Long-term treatment strategies for atherothrombotic disease: do platelets define the course?. Eur Heart J Suppl
10: I8-I13
[Abstract][Full Text]
Husted, S.
(2008). Benefits and risks with antiplatelet therapy: how great a problem is bleeding?. Eur Heart J Suppl
10: I19-I24
[Abstract][Full Text]
Vlaar, P. J., Svilaas, T., Damman, K., de Smet, B. J.G.L., Tijssen, J. G.P., Hillege, H. L., Zijlstra, F.
(2008). Impact of Pretreatment With Clopidogrel on Initial Patency and Outcome in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Systematic Review. Circulation
118: 1828-1836
[Abstract][Full Text]
Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., Johnston, S. C., Steinhubl, S. R., Mak, K.-H., Easton, J. D., Hamm, C., Hu, T., Fox, K. A.A., Topol, E. J., on behalf of the Clopidogrel for High Atherothromb,
(2008). Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk. Circulation
118: 1705-1712
[Abstract][Full Text]
McKellar, S. H., Thompson, J. L. III, Garcia-Rinaldi, R. F., MacDonald, R. J., Sundt, T. M. III, Schaff, H. V.
(2008). Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine.. J. Thorac. Cardiovasc. Surg.
136: 908-914
[Abstract][Full Text]
Mauri, L., Silbaugh, T. S., Garg, P., Wolf, R. E., Zelevinsky, K., Lovett, A., Varma, M. R., Zhou, Z., Normand, S.-L. T.
(2008). Drug-Eluting or Bare-Metal Stents for Acute Myocardial Infarction. NEJM
359: 1330-1342
[Abstract][Full Text]
Shishehbor, M. H., Goel, S. S., Kapadia, S. R., Bhatt, D. L., Kelly, P., Raymond, R. E., Galla, J. M., Brener, S. J., Whitlow, P. L., Ellis, S. G.
(2008). Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. J Am Coll Cardiol
52: 1041-1048
[Abstract][Full Text]
Stone, G. W.
(2008). Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part I: Primary Percutaneous Coronary Intervention. Circulation
118: 538-551
[Full Text]
Bates, E. R., Nallamothu, B. K.
(2008). Commentary: The Role of Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction. Circulation
118: 567-573
[Full Text]
White, H. D.
(2008). Systems of Care: Need for Hub-and-Spoke Systems for Both Primary and Systematic Percutaneous Coronary Intervention After Fibrinolysis. Circulation
118: 219-222
[Full Text]
Dunning, J., Versteegh, M., Fabbri, A., Pavie, A., Kolh, P., Lockowandt, U., Nashef, S. A.M., on behalf of the EACTS Audit and Guidelines Commit,
(2008). Guideline on antiplatelet and anticoagulation management in cardiac surgery.. Eur. J. Cardiothorac. Surg.
34: 73-92
[Abstract][Full Text]
Sullivan, J., Amarshi, N.
(2008). Dual antiplatelet therapy with clopidogrel and aspirin. Am J Health Syst Pharm
65: 1134-1143
[Abstract][Full Text]
Schiele, F., Meneveau, N., Bassand, J.-P.
(2008). Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer?. Eur Heart J
29: 1475-1477
[Full Text]
Natarajan, A., Zaman, A. G, Marshall, S. M
(2008). Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diabetes and Vascular Disease Research
5: 138-144
[Abstract]
Weintraub, W. S.
(2008). Pharmacoeconomic Concepts in Antiplatelet Therapy: Understanding Cost-Effectiveness Analyses Using Clopidogrel as an Example. J CARDIOVASC PHARMACOL THER
13: 107-119
[Abstract]
Patrono, C., Baigent, C., Hirsh, J., Roth, G.
(2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 199S-233S
[Abstract][Full Text]
Goodman, S. G., Menon, V., Cannon, C. P., Steg, G., Ohman, E. M., Harrington, R. A.
(2008). Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 708S-775S
[Abstract][Full Text]
Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., Harrington, R. A.
(2008). The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 776S-814S
[Abstract][Full Text]
Toyoda, K., Yasaka, M., Iwade, K., Nagata, K., Koretsune, Y., Sakamoto, T., Uchiyama, S., Gotoh, J., Nagao, T., Yamamoto, M., Takahashi, J. C., Minematsu, K., for the Bleeding with Antithrombotic Therapy (BAT),
(2008). Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease: A Prospective, Multicenter, Observational Study. Stroke
39: 1740-1745
[Abstract][Full Text]
Morrow, D. A.
(2008). Antithrombotic Therapy to Support Primary PCI. NEJM
358: 2280-2282
[Full Text]
Cairns, J. A., Eikelboom, J.
(2008). Clopidogrel Resistance: More Grist for the Mill. J Am Coll Cardiol
51: 1935-1937
[Full Text]
Busk, M., Maeng, M., Rasmussen, K., Kelbaek, H., Thayssen, P., Abildgaard, U., Vigholt, E., Mortensen, L. S., Thuesen, L., Kristensen, S. D., Nielsen, T. T., Andersen, H. R., for the DANAMI-2 Investigators,
(2008). The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. Eur Heart J
29: 1259-1266
[Abstract][Full Text]
Sabatine, M. S., Morrow, D. A., Higgins, L. J., MacGillivray, C., Guo, W., Bode, C., Rifai, N., Cannon, C. P., Gerszten, R. E., Lee, R. T.
(2008). Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction. Circulation
117: 1936-1944
[Abstract][Full Text]
Kapoor, J. R., Patrono, C., Davi, G.
(2008). Platelet Activation and Atherothrombosis. NEJM
358: 1638-1639
[Full Text]
O'Donoghue, M., Morrow, D. A., Cannon, C. P., Guo, W., Murphy, S. A., Gibson, C. M., Sabatine, M. S.
(2008). Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J
29: 984-991
[Abstract][Full Text]
BAKHRU, M. R., BHATT, D. L.
(2008). INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin?. Cleveland Clinic Journal of Medicine
75: 289-295
[Abstract][Full Text]
Henriksen, P. A., Palmer, K., Boon, N. A.
(2008). Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy. QJM
101: 261-267
[Abstract][Full Text]
Reaume, K. T, Regal, R. E, Dorsch, M. P
(2008). Indications for Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Evidence-Based Recommendations for Use. The Annals of Pharmacotherapy
42: 550-557
[Abstract][Full Text]
Michelson, A. D.
(2008). P2Y12 Antagonism: Promises and Challenges. Arterioscler. Thromb. Vasc. Bio.
28: s33-s38
[Abstract][Full Text]
Gibson, C. M., Pride, Y. B., Buros, J. L., Lord, E., Shui, A., Murphy, S. A., Pinto, D. S., Zimetbaum, P. J., Sabatine, M. S., Cannon, C. P., Josephson, M. E., for the TIMI Study Group,
(2008). Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.. J Am Coll Cardiol
51: 546-551
[Abstract][Full Text]
Li, J. S., Yow, E., Berezny, K. Y., Bokesch, P. M., Takahashi, M., Graham, T. P. Jr, Sanders, S. P., Sidi, D., Bonnet, D., Ewert, P., Jennings, L. K., Michelson, A. D., for the PICOLO Investigators,
(2008). Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial. Circulation
117: 553-559
[Abstract][Full Text]
American College of Cardiology/American Heart Asso, , Developed in Collaboration With the Canadian Cardi, , Endorsed by the American Academy of Family Physici, , 2007 Writing Group to Review New Evidence and Upda, , Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., Halasyamani, L. K., Hochman, J. S., Krumholz, H. M., Lamas, G. A., Mullany, C. J., Pearle, D. L., Sloan, M. A., Smith, S. C. JR
(2008). 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol
51: 210-247
[Full Text]
American College of Cardiology/American Heart Asso, , 2007 Writing Group to Review New Evidence and Upda, , King, S. B. III, Smith, S. C. Jr, Hirshfeld, J. W. Jr, Jacobs, A. K., Morrison, D. A., Williams, D. O.
(2008). 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. J Am Coll Cardiol
51: 172-209
[Full Text]
Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., Halasyamani, L. K., Hochman, J. S., Krumholz, H. M., Lamas, G. A., Mullany, C. J., Pearle, D. L., Sloan, M. A., Smith, S. C. Jr, 2004 Writing Committee Members, , Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., Mullany, C. J., Ornato, J. P., Pearle, D. L., Sloan, M. A., Smith, S. C. Jr, Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Buller, C. E., Creager, M. A., Ettinger, S. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B., Tarkington, L. G., Yancy, C. W.
(2008). 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation
117: 296-329
[Full Text]
King, S. B. III, Smith, S. C. Jr, Hirshfeld, J. W. Jr, Jacobs, A. K., Morrison, D. A., Williams, D. O., 2005 WRITING COMMITTEE MEMBERS, , Smith, S. C. Jr, Feldman, T. E., Hirshfeld, J. W. Jr, Jacobs, A. K., Kern, M. J., King, S. B. III, Morrison, D. A., O'Neill, W. W., Schaff, H. V., Whitlow, P. L., Williams, D. O., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Buller, C. E., Creager, M. A., Ettinger, S. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B., Tarkington, L. G., Yancy, C. W.
(2008). 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation
117: 261-295
[Full Text]
Gitt, A. K., Betriu, A.
(2008). Antiplatelet therapy in acute coronary syndromes. Eur Heart J Suppl
10: A4-A12
[Abstract][Full Text]
Bode, C., Huber, K.
(2008). Antiplatelet therapy in percutaneous coronary intervention. Eur Heart J Suppl
10: A13-A20
[Abstract][Full Text]
Bertrand, M. E.
(2008). When and how to discontinue antiplatelet therapy. Eur Heart J Suppl
10: A35-A41
[Abstract][Full Text]
Jones, J B, Docherty, A
(2007). Non-invasive treatment of ST elevation myocardial infarction. Postgrad. Med. J.
83: 725-730
[Abstract][Full Text]
Bhatt, D. L.
(2007). Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis. NEJM
357: 2078-2081
[Full Text]
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., Antman, E. M., the TRITON-TIMI 38 Investigators,
(2007). Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. NEJM
357: 2001-2015
[Abstract][Full Text]
Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Peters, G., Storey, R. F., for the DISPERSE-2 Investigators,
(2007). Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial. J Am Coll Cardiol
50: 1844-1851
[Abstract][Full Text]
Bhatt, D. L., Flather, M. D., on behalf of the CHARISMA Executive Committee and,
(2007). Reply. J Am Coll Cardiol
50: 1704-1705
[Full Text]
Dobrzycki, S., Kralisz, P., Nowak, K., Prokopczuk, P., Kochman, W., Korecki, J., Poniatowski, B., Zuk, J., Sitniewska, E., Bachorzewska-Gajewska, H., Sienkiewicz, J., Musial, W. J
(2007). Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals. Eur Heart J
28: 2438-2448
[Abstract][Full Text]
Wang, T. H., Bhatt, D. L., Fox, K. A.A., Steinhubl, S. R., Brennan, D. M., Hacke, W., Mak, K.-H., Pearson, T. A., Boden, W. E., Steg, P. G., Flather, M. D., Montalescot, G., Topol, E. J., on behalf of the CHARISMA Investigators,
(2007). An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J
28: 2200-2207
[Abstract][Full Text]
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., Antman, E. M.
(2007). Diabetes and Mortality Following Acute Coronary Syndromes. JAMA
298: 765-775
[Abstract][Full Text]
Van de Werf, F.
(2007). Dual antiplatelet therapy in high-risk patients. Eur Heart J Suppl
9: D3-D9
[Abstract][Full Text]
Schneider, D. J., Sobel, B. E.
(2007). Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs. Circulation
116: 305-315
[Full Text]
Kiernan, T. J., Ting, H. H., Gersh, B. J.
(2007). Facilitated percutaneous coronary intervention: current concepts, promises, and pitfalls. Eur Heart J
28: 1545-1553
[Abstract][Full Text]
Sabatine, M. S., Morrow, D. A., Dalby, A., Pfisterer, M., Duris, T., Lopez-Sendon, J., Murphy, S. A., Gao, R., Antman, E. M., Braunwald, E., for the ExTRACT-TIMI 25 Investigators,
(2007). Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With ST-Segment Elevation Myocardial Infarction Also Treated With Clopidogrel. J Am Coll Cardiol
49: 2256-2263
[Abstract][Full Text]
Fox, K. A.A., Antman, E. M., Montalescot, G., Agewall, S., SomaRaju, B., Verheugt, F. W.A., Lopez-Sendon, J., Hod, H., Murphy, S. A., Braunwald, E.
(2007). The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial. J Am Coll Cardiol
49: 2249-2255
[Abstract][Full Text]
Birnbaum, Y., Lin, Y., Ye, Y., Martinez, J. D., Huang, M.-H., Lui, C. Y., Perez-Polo, J. R, Uretsky, B. F.
(2007). Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am. J. Physiol. Heart Circ. Physiol.
292: H2891-H2897
[Abstract][Full Text]
Spinler, S. A.
(2007). Managing acute coronary syndrome: Evidence-based approaches. Am J Health Syst Pharm
64: S14-S24
[Abstract][Full Text]
Alexander, K. P., Newby, L. K., Cannon, C. P., Armstrong, P. W., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., Gore, J. M., Krumholz, H. M., Ohman, E. M.
(2007). Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology. Circulation
115: 2549-2569
[Abstract][Full Text]
Alexander, K. P., Newby, L. K., Armstrong, P. W., Cannon, C. P., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., Gore, J. M., Krumholz, H. M., Ohman, E. M.
(2007). Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology. Circulation
115: 2570-2589
[Abstract][Full Text]
Meadows, T. A., Bhatt, D. L.
(2007). Clinical Aspects of Platelet Inhibitors and Thrombus Formation. Circ. Res.
100: 1261-1275
[Abstract][Full Text]